Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.08 USD | +2.86% | -10.82% | -26.20% |
Financials (USD)
Sales 2024 * | 149M | Sales 2025 * | 192M | Capitalization | 184M |
---|---|---|---|---|---|
Net income 2024 * | -16M | Net income 2025 * | 18M | EV / Sales 2024 * | 1.23 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.96 x |
P/E ratio 2024 * |
-12
x | P/E ratio 2025 * |
12.3
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.89% |
Latest transcript on Rigel Pharmaceuticals, Inc.
1 day | -5.41% | ||
1 week | -14.63% | ||
Current month | -29.05% | ||
1 month | -21.64% | ||
3 months | -21.64% | ||
6 months | +10.61% | ||
Current year | -27.59% |
Managers | Title | Age | Since |
---|---|---|---|
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 00-03-31 |
Dean Schorno
DFI | Director of Finance/CFO | 61 | 18-05-28 |
Chief Tech/Sci/R&D Officer | - | 16-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gregg Lapointe
CHM | Chairman | 65 | 17-11-01 |
Gary Lyons
BRD | Director/Board Member | 73 | 05-09-30 |
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 00-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 509 M€ | -.--% | ||
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1.077 | +2.58% | 72 396 |
24-04-18 | 1.05 | -5.41% | 1,237,672 |
24-04-17 | 1.11 | -2.63% | 578,022 |
24-04-16 | 1.14 | -0.87% | 754,958 |
24-04-15 | 1.15 | -4.17% | 768,566 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.59% | 184M | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.43% | 21.66B | |
-18.35% | 20.77B | |
-8.72% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- RIGL Stock